Preclinical development of Q2361, a transforming new drug for skin cancer prevention in organ transplant recipients

接受器官移植的患者需要额外的药物来防止器官排斥反应。不幸的是，这些药物带来了不受欢迎的副作用--它们会导致皮肤癌的发生。目前，除了手术，对这些患者的帮助微乎其微。我们的初步数据表明，一种新药可能会阻止这些皮肤癌的形成。该项目旨在提供对该药物的影响及其在皮肤癌预防中的作用的关键见解。

Patients that receive organ transplants need additional medications in order to prevent organ rejection. Unfortunately, these drugs carry an unwanted side-effect - they permit the development of skin cancer. Currently, other than surgery, little can be done to help these patients. Our preliminary data suggest that a new drug may prevent these skin cancers from forming. This project aims to deliver key insights into the influence of this drug and its role in skin cancer prevention.